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Abstract: Streptozocin has been shown to be useful in the clinical treatment of malignant neuroendocrine tumors of the 
pancreas. The poor prognosis for patients having malignant tumors of pancreas suggests the investigation and develop-
ment of new therapeutics. Nine analogs to streptozocin are determined by in silico physicochemical analysis and genera-
tion of structures by modeling from functional group isosteres. In these analogs is preserved the alkylating nitrosourea 
moiety, however, the covalently bonded substituent has significant hydrogen bonding sites and may include a ring struc-
ture. Analogs retain a broad range in lipophilicity, having a range of Log P from -2.798 (hydrophilic) to 3.001 (lipophilic). 
Standard deviation of molecular masses is only 12.6% of the group mean, so a small alteration in size occurs which is also 
reflected by only a 15.5% deviation in molecular volumes. Streptozocin and seven analogs show zero violations of the 
Rule of 5 which suggests favorable bioavailability. All compounds showed at least seven hydrogen bond acceptors with a 
strong positive correlation between hydrophilicity to the total number of hydrogen bond acceptors and donors. Analysis of 
similarity (ANOSIM) and discriminant analysis determined that streptozocin is highly similar to all nine analogs. How-
ever hierarchical cluster analysis and K-means cluster analysis were able to elucidate patterns of associations and differen-
tiation among the ten compounds. This study demonstrates the efficacy of utilizing in silico optimization and pattern rec-
ognition to elucidate potential anticancer drugs. 
INTRODUCTION 
  Pancreatic cancer is a deadly malignant tumor of the pan-
creas which kills tens of thousands in the United States and 
Europe each year. Approximately 95% of all pancreatic can-
cers are adenocarcinomas and 5% include serous cystadeno-
mas, acinar cell cancers, and neuroendocrine tumors. The 
neuro-endocrine system is the interface between the messen-
ger nervous system and hormone system acting as messenger 
to regulate physiological activity. Gastro entero pancreatic 
neuroendocrine tumors, or GEP-NETs, are cancers at the 
nervous-endocrine system interface and include carcinoids 
(slow growing) and pancreatic endocrine tumors. Islet cell 
tumors or endocrine pancreatic tumors (EPTs) are thought to 
originate in the islets of Langerhans of the pancreas. 
Roughly 2% of pancreatic tumors belong to the GEP-NET 
class. 
  Streptozocin is a glucosamine-nitrosourea that is an 
alkylating antineoplastic agent that falls with in the 
nitrosourea class of drugs and is particularly toxic to insulin 
producing beta cells of the pancreas [1]. Streptozocin itself 
has a molecular structure that resembles glucose and can be 
transported into the cell by glucose transport proteins such as 
GLUT2 [1]. Beta cells of the pancreas have a large number 
of GLUT2 glucose transporters such that induced toxicity is 
substantial, whereas other glucose transporters do not recog-
nize streptozocin [2, 3]. This fact played a significant role in 
the application of streptozocin in the treatment of pancreatic  
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islet cell cancer [4]. Streptozocin is mutagenic, teratogenic, 
carcinogenic, and can cross the placenta [1-3]. The typical 
dose of streptozocin is administered intravenously because it 
has poor oral absorption. Streptozocin degrades to a methyl-
carbonium ion with only a small fraction of administered 
dose excreted in the kidneys. 
  Streptozocin has been studied as part of a combination 
chemotherapy for advanced cancer of the pancreas [5]. Re-
sponse rates for treatment of pancreatic cancer using strepto-
zocin, fluorouracil, and semustine together were greater than 
that achieved with treatment by melphalan alone [5]. Pancre-
atic islet cell carcinoma treated with a combination regimen 
of streptozocin with fluorouracil showed a reduction in the 
size of the enlarged metastatic tumor, with improved liver 
enzymes, and accompanied with only mild toxic reaction [6]. 
Other investigators have observed considerable success with 
streptozocin and doxorubicin combination chemotherapy for 
malignant neuroendocrine pancreatic tumors [7]. Up to 60% 
of patients receiving streptozocin/doxorubicin regimen gave 
a favorable response and survival benefit [7]. Other studies 
provide supporting results, showing that streptozocin, 
doxorubicin, and fluorouracil in combination brought about a 
response rate of 39% with longer progression free survival 
and overall survival for treatment of islet cell cancer (pan-
creatic endocrine carcinoma) [8]. A study was performed 
comparing combination chemotherapy of a streptozocin-
doxorubicin pair with a streptozocin-fluorouracil pair [9]. 
The relative tumor regression rate was 69% and 45%, re-
spectively, demonstrating the superiority of the streptozocin-
doxorubicin combination [9]. In addition the streptozocin-
doxorubicin regimen had a significant advantage in long 
term survival [9]. These encouraging results clearly support 82    The Open Medicinal Chemistry Journal, 2008, Volume 2  Ronald Bartzatt 
the contention that the design of novel antineoplastic drugs 
utilizing streptozocin as a parent modeled compound may 
render effective agents for use in the clinical treatment of 
pancreatic islet cell (neuroendocrine) carcinoma. 
MATERIALS AND METHODOLOGY 
Molecular Modeling and Assembly of Constructs 
  Numerical values of molecular properties and molecular 
modeling were accomplished utilizing ACD/Chem Sketch 
modeling v. 10.00 (Advanced Chemistry Development, 110 
Yonge Street, Toronto Ontario, M5C 1T4 Canada). Other 
properties; polar surface area, violations of Rule of 5, mo-
lecular volume, number of oxygens/nitrogens/amines/hydro-
xyls, etc were determined using Molinspiration (Molinspira-
tion Chemiformatics, Nova ulica 61, SK-900 26 Slovensky 
Grob, Slovak Republic). The determination of drug-likeness 
for all compounds was accomplished for GPCR (G protein-
coupled receptor) ligand activity, ion channel modulator ac-
tivity, kinase inhibition, and nuclear receptor ligand activity 
by Molinspiration. Visualization of 3-dimensional scaffold-
ing was achieved by utilizing SPARTAN modeling (Wave-
function, 18401 Von Darman Avenue, Irvine CA 92612 
USA). 
Pattern Recognition Analysis 
  To identify underlying associations/patterns within the 
molecular properties numerical matrix various pattern recog-
nition techniques were applied. Included in this application 
is hierarchical cluster analysis accomplished by KyPlot v. 
2.0 Beta 15 (copyright Koichi Yoshioka 1997-2001). Dis-
criminant analysis, and non-hierarchical K-means cluster 
analysis were performed by PAST v. 1.80 (copyright Oyvind 
Hammer, D.A.T. Harper 1999-2008). 
Numerical Analysis of Multivariate Matrix Field 
  Statistical analysis of all numerical data was performed 
by Microsoft EXCEL (EXCEL 2003, copyright 1985-2003). 
Multiple regression analysis of molecular property values 
was accomplished by GraphPad Instat v. 3.00 for Windows 
95 (GraphPad Software, San Diego California USA). Corre-
lation analysis for Pearson r was done for descriptors indi-
cated and was accomplished by EXCEL (2003) and PAST. 
RESULTS 
  Streptozocin is currently utilized in the clinical treatment 
of pancreatic islet cell carcinoma. The molecular structure of 
streptozocin is presented in Fig. (1), and was used as the 
parent (to be modeled) compound for development of mo-
 
Fig. (1). The molecular structures of the parent compound streptozocin and nine chemical analogs are presented here for comparison. Note 
that all compounds, excepting number 10, have a ring substituent. The nitrosourea moiety comprises the alkylating functional group of the 
structure. Many compounds have substantial hydrogen bonding donor/acceptor sites. The secondary amide nitrogen atom of all compounds 
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lecular analogs that may have effectiveness in cancer treat-
ment. The nine analogs derived are also presented in Fig. (1) 
and have numerous features in common with the parent 
streptozocin. They include as follows by inspection: i) A 
nitrosourea alkylating moiety; ii) A secondary amide group 
having a hydrogen covalently bonded to the nitrogen atom; 
iii) A non-alkylating substituent; iv) Except for analog 10, all 
drugs have a ring substituent; v) The non-alkylating substitu-
ent has hydrogen donor/acceptor capability. 
  Various molecular properties that have substantial phar-
macological importance were determined for the parent 
streptozocin and the nine analogs. These properties (descrip-
tors) include: Log P (lipophilicity), polar surface area (PSA), 
number of heavy atoms, formula weight, number of rotatable 
bonds, hydrogen bonding centered atoms (nitrogens, oxy-
gen), molecular volume, and violations of Rule of 5. All 
drugs together showed a broad range in lipophilicity, with a 
range of Log P from -2.798 (hydrophilic) to 3.001 (lipo-
philic). Standard deviation of molecular mass is 12.6% of the 
mean, therefore a small alteration in size occurs which is also 
reflected by only a 15.5% deviation in molecular volume. 
Streptozocin and seven analogs show zero violations of the 
Rule of 5, analogs 6 and 9 showed one violation. All com-
pounds showed at least seven hydrogen bond acceptors with 
a strong correlation between hydrophilic tendency to the 
total number of hydrogen bond acceptors and donors. Corre-
lation of drug by properties determined for the ten com-
pounds was determined using Pearson r and produced very 
high drug-to-drug correlation based on the properties pre-
sented in Table 1. All inter-drug correlation r values were 
greater than 0.9500. The outcome of Analysis of Similarity 
(ANOSIM) presented a value of 0.1081. In addition to Pear-
son r and ANOSIM for correlation and similarity, respec-
tively, underlying relationships among the ten drugs can be 
investigated by use of non-hierarchical K-means analysis. 
This was done for two cluster outcome and should the fol-
lowing clustering based on similarity: Cluster 1) Drug 1 
(streptozocin), 3, 5, 6, 8, and 10; Cluster 2) Drug 2, 4, 7, and 
9. For three cluster outcome the clustering results were as 
follows: Cluster 1) Drug 1 (streptozocin), 3, 5, 6, 8, and 10; 
Cluster 2) Drug 2, 7, and 9; Cluster 3) Drug 4 only. Finally, 
for the four cluster outcome the clustering results were as 
follows: Cluster 1) Drug 2 and 9; Cluster 2) Drug 4 and 7; 
Cluster 3) Drug 5 and 8; Cluster 4) Drug 1 (streptozocin), 3, 
6, and 10. 
  To derive an equation for supporting the design and de-
scription of antineoplastic nitrosoureas that are related to 
streptozocin, multiple regression was accomplished for for-
mula weight as dependent variable and Log P, PSA, and 
number of atoms as independent variables. The outcome 
equation as follows: 
formula weight = -28.150 + (2.748)(Log P) + (0.3283)(PSA) 
+ (13.984) (number of atoms). 
  The value of R squared was 0.9643, therefore the model 
explains 96.43% of variance in the formula weight. 
  Subtle associations among the ten drugs can be eluci-
dated by applying a more sensitive determinate of similarity 
utilizing hierarchical cluster analysis. Utilizing the numerical 
matrix presented in Table 1 it is possible to reveal then un-
derlying relationships not apparent by inspection. The out-
come of cluster analysis is seen in Fig. (2), where drugs 1 to 
10 are grouped into clusters determined to indicate the high-
est degree of similarity (based on numerical values of de-
sired molecular properties). The drugs are grouped as pairs: 
1 (streptozocin) and 3, 5 and 8, 2 and 9, 4 and 7, with drugs 
6 and 10 associated with 1 and 3 by supernode (higher clus-
ter having greater distance (Euclidean) from the rudimentary 
clusters). 
  Discriminant analysis (DA) was performed on all drugs 
using properties of Table 1. DA is useful in identifying de-
scriptors that distinguish subjects from among a multivariate 
matrix. This pattern recognition is also sensitive and can 
identifying subjects that may be outliers from within a mul-
tivariate collection. DA was carried out and outcome is pre-
sented in Fig. (3) as a 2-way plot wherein the closer proxim-
ity between subjects suggests greater similarity. Clearly visi-
ble is the strong clustering of all ten compounds into very 
close proximity and therefore showing very high similarity. 
Table 1.  Molecular Properties of Streptozocin and Analogs 
 
Compound Log  P 
Polar Surface  
Area  
(Angstroms
2) 
Number of  
Atoms 
Formula  
Weight 
Number of  
Oxygens and  
Nitrogens 
Number of  
Amines and  
Hydroxyls 
Number  
of Rotatable  
Bonds 
Molecular  
Volume  
(Angstroms
3) 
Violations of  
Rule of 5 
1 Streptozocin  -2.088  151.917   18  265.222   10   5   3   219.350   0 
2 -0.647  140.923   21  327.721   10   4   6   267.454   0 
3 -1.869  151.917   18  265.222   10    5   3   219.350   0 
4 3.001   91.233   24  339.436   7   2   8   324.502   0 
5 -0.14  106.262   17  246.267   8   3   4    223.496   0 
6 -2.798  157.712   18  264.238   10   6   3   222.618   1 
7 1.484  103.25   21  302.375   8   3   9   291.627   0 
8 2.234   80.209   18  257.29   7   1   3   235.422   0 
9 -1.885  161.151   21  309.275   11   5   6   261.936   1 
10 -1.597  142.683   16  237.212   9   5   6   204.351   0 84    The Open Medicinal Chemistry Journal, 2008, Volume 2  Ronald Bartzatt 
 
Fig. (2). Hierarchical cluster analysis results distinguish the analogs 
for parent by molecular properties. Useful in estimating potential 
significant physicochemical divergence from the parent streptozo-
cin (1) and analogs. Streptozocin is most similar to analog 3 but 
related to analogs 6 and 10 (see Table 1). Remaining analogs are 
paired within clusters as follows: 5 and 8, 2 and 9, 4 and 7. 
 
 
Fig. (3). Results for discriminant analysis presented within a 2-way 
plot indicate clearly that streptozocin (1) and analogs are very simi-
lar and are positioned in close proximity to each other. Plotted 
along discriminant group 1 and 2, these compounds are highly clus-
tered and hence quite similar. 
  Activity of all nine analogs and streptozocin were rigor-
ously analyzed under four criteria of known successful drug 
activity in the areas of GPCR ligand activity, ion channel 
modulation, kinase inhibition activity, and nuclear receptor 
ligand activity (see Materials and Methodology). Results are 
shown for all ten compounds in Table 2 by means of nu-
merical assignment. Numerical values of streptozocin (drug 
1) are presented in column 1 and have consistent negative 
values placing streptozocin outside the numerical range of 
values for current therapeutic agents used in each category 
(clinical drugs have values from zero to two). Likewise ana-
logs 2 through 10 have consistent negative values in all cate-
gories and numerical values conforming and comparable to 
that of streptozocin. Pearson r correlation was calculated to 
show extremely high correlation of streptozocin to drugs 2, 
3, 4, 5, 6, 7, 8, and 10 (r > 0.8400) and very high correlation 
to drug 9 (r > 0.7600). Therefore it is readily seen that ana-
logs 2 through 10 are expected to have similar activity to 
streptozocin based upon these four rigorous criteria (GPCR 
ligand, ion channel modulator, (kinase inhibitor, and nuclear 
receptor ligand). 
DISCUSSION 
  Streptozocin has been found to enhance the clinical 
treatment of advance pancreatic neuroendocrine carcinoma 
when administered in combination chemotherapy [5-9]. 
Streptozocin is a nitroso-urea alkylating agent with a het-
eroatom ring substituent having four hydrogen bond donors 
and one acceptor. That portion of the molecule is hydrophilic 
and contributes significantly to the Log P value of -2.088 
and polar surface area of 151.917 A
2 (see Table 1). Previous 
studies have shown that this PSA value seriously impedes 
oral bioavailability [10]. Only for analogs 4 and 8 (see Fig. 
(1) and Table 1) do the values of PSA become less than 100 
A
2 to be 91.233 A
2 and 80.239 A
2, respectively, suggesting 
intestinal absorption of about 50% and 75%, respectively. 
Clearly than a change in PSA could have substantial affect 
on administration of analogs 4 and 8 that may be beneficial 
to the patient. To support this contention, note that analogs 4 
and 8 have zero violations of the Rule of 5. The Rule of 5 is 
a set of parameters devised to aid the screening of potential 
drug “hits” identified through processes such as high 
throughout screening [11]. Applying the Rule of 5 increases 
the probability that a potential chemotherapeutic will have 
favorable bioavailability. The criteria are as as follows [11]: 
A) Not more than 5 hydrogen bond donors; B) Not more 
than 10 hydrogen bond acceptors; C) Formula weight less 
than 500; and D) Log P less than 5. Two or more violations 
of the Rule of 5 suggests the probability of problems in 
bioavailability [11]. All analogs excepting 6 and 9 have zero 
violations of the Rule of 5. The small deviation from average 
molecular mass, number of heavy atoms (19.2+2.4), and 
molecular volume for all ten compounds suggests adherence 
to preservation of atom type and functional group presence 
in these in silico optimized designs. 
  Pattern recognition methods offer great advantages for 
the mechanism of drug design, especially in both biological 
and physiochemical calculation and collation of data having 
computer databases, molecular modeling systems, and prop-
erty prediction packages [12-14]. K-means cluster analysis is 
a non-hierarchical clustering method where the outcome 
number of clusters must be designated by the investigators 
[15]. Highest resolution determined at four cluster outcome, 
the clustering results were as follows: Cluster 1) Drug 2 and 
9; Cluster 2) Drug 4 and 7; Cluster 3) Drug 5 and 8; Cluster 
4) Drug 1 (streptozocin), 3, 6, and 10. Initial inspection re-
veals that streptozocin is determined to be most similar to 
analogs 3, 6, and 10, an outcome identical to hierarchical 
cluster analysis (Fig. 2). Viewing the molecular structures Design of Anticancer Agents Utilizing Streptozocin for In Silico Optimization  The Open Medicinal Chemistry Journal, 2008, Volume 2    85 
(Fig. 1) of 1, 3, 6, and 10 reveals that only analog 10 does 
not have a ring substituent but an aliphatic chain on which 
there are located four hydrogen bond donors (-OH). Each of 
1, 3, 6, and 10 have Log P values less than zero and PSA 
greater than 140 A
2. Consistency of isosteres along with Log 
P and PSA suggests analogs 3, 6, and 10 may be a useful 
alternative to streptozocin (Note that there is also high con-
sistency among 1, 3, 6, and 10 in number of heavy atoms and 
molecular volume). ANOSIM implements a statistical test 
whether there is a considerable difference between two or 
more groups of sampling data [16]. A large value of R of up 
to 1.000 signifies dissimilarity among groups whereas a low 
R approaching zero signifies high similarity [16]. The R 
value of 0.1081 signifies that streptozocin and these nine 
analogs are highly similar, a outcome substantiated by re-
sults of discriminant analysis (see Fig. 3). 
  Hierarchical cluster analysis displays outcome as a hori-
zontal or vertical dendrogram depicting the assembly of sub-
jects within clusters so that highest similarity lies with sub-
jects found in identical clusters and lowest similarity among 
more distant clusters [14]. Dendrograms can provide a dis-
tance measurement along one axis to represent relative sepa-
ration among the clusters. Viewing Fig. (2) is apparent that 
streptozocin (1) is most similar to analog 3 (also suggested 
by K-means cluster analysis and discriminant analysis), but 
associated with analog 6 and 10 by branching to a super-
node. The remaining analogs are paire as 5 and 8, 2 and 9, 4 
and 7. Again, analogs 3, 6, and 10 are determined to be pos-
sible alternatives to streptozocin. 
  When given two sets of multivariate data, discriminant 
analysis constructs an axis that functions to maximize the 
differences between the two sets [17]. Discriminant analysis 
(DA) can investigate differences among groups, determine 
the most facile manner to distinguish groups, and asses the 
relative importance of independent variables [17]. Inspection 
of the 2-way axis presented in Fig. (3) representing outcome 
by DA show clustered subjects (drugs) along group 1 axis 
and group 2 axis. Although the plot shows all drugs in prox-
imity, analog 3 is near identical to streptozocin (1) with ana-
log 6 and 2 closest. Supporting ANOSIM and K-means clus-
ter analysis outcome, streptozocin is still highly similar to 
analogs 1 to 9 but determined to have highest similarity to 
analog 3 and 6. No critical schism among the parent com-
pound and structural analogs is discerned by DA. The con-
tribution of Log P, PSA, and number of atoms have been 
shown to play an important role in establishing similar drug 
likeness (multiple regression R squared 0.9643) however the 
Pearson r correlation coefficient greater than 0.9500 (for all 
drugs) show considerable association of each drug by all 
descriptors that were calculated (Table 1). Consequently it is 
clear that construction of nitrosoureas analogous to strepto-
zocin produces viable alternatives that have many consistent 
features in hydrogen bond donor/acceptor sums, PSA, mo-
lecular weight and volume. Altogether an in silico construc-
tion of analogous structures, controlled by restrictions in 
functional group and isosteric encompassment, produced 
potential chemotherapeutic tools for clinical treatment of 
pancreatic related carcinoma. Pattern recognition methods 
elucidated and resolved underlying associations of these ana-
logs to the parent compound based upon the numerical val-
ues of various critical pharmaceutical properties. 
  When evaluating the expected bio-activity of novel drug 
structures it is very useful to apply a screening criteria to 
populations of the potential drug candidates. A filtering of 
potential drug constructs can be achieved by implementing 
Bayesian statistics in comparing molecular structures of 
known successful active molecules to novel constructs. All 
ten compounds were analyzed in this manner (see Materials 
and Methodology) under the criteria of GPCR ligand activ-
ity, ion channel modulation, kinase inhibition, and nuclear 
receptor ligand activity giving results presented in Table 2 
that are very highly correlated to streptozocin (no Pearson r 
value is less than 0.7600). Also, the numerical values of the 
activities determined for analogues 2 through 10 are consis-
tent and comparable to that of streptozocin. 
  This further supports the outcome that analogs 2 through 
10 are substantially alike streptozocin and with congruent 
drug-likeness. 
CONCLUSION 
  Utilizing streptozocin as parent, nine molecular analogs 
were contrived that retained the alkylating moiety and 
thereby the antineoplastic activity. The analogs were suffi-
ciently varied from the parent to possess a broad range of 
lipophilic character, revealed by Log P, yet retain adequate 
features to have Pearson r correlation of greater than 0.9500 
among each other (based on properties presented in Table 1). 
This observation supported by an ANOSIM value of 0.1081, 
indicating substantial similarity. In addition to these out-
comes, discriminant analysis determined that all drugs were 
highly analogous within the descriptors applied, with dis-
criminant scores showing close proximity clustering within a 
2-way plot. 
  All compounds excepting analogs 6 and 9 were deter-
mined to express zero violations to the Rule of 5, hence an 
indication of favorable bioavailability based on drug like-
Table 2.  Drug-Likeness Scores Based on Activity 
 
Activity  Of  Drug-Likenss  1 2 3 4 5 6 7 8  9  10 
GPCR  ligand  -1.62 -1.87 -1.45 -0.78 -1.23 -1.33 -0.56 -1.22  -1.30  -1.87 
Ion  Channel  Modulator  -1.16 -1.61 -1.13 -0.57 -0.57 -1.17 -0.38 -0.96  -1.31  -0.96 
Kinase  Inhibitor  -1.66 -1.80 -1.90 -1.14 -1.64 -1.60 -0.96 -1.88  -1.56  -1.71 
Nuclear  Receptor  Ligand  -1.90 -2.24 -2.41 -1.23 -2.47 -2.16 -1.76 -1.88  -2.27  -2.28 
Drug 1 = Streptozocin. 86    The Open Medicinal Chemistry Journal, 2008, Volume 2  Ronald Bartzatt 
ness. The considerable number of hydrogen donor/acceptor 
atoms incurred significant hydrophilic character into the ma-
jority of these drugs (supported by Log P values less than 0). 
Non-hierarchical K-means clustering at highest resolution 
showed the parent streptozocin to be closest to analogs 3, 6, 
and 10. Multiply regression analysis determined an equation 
relating formula weight to descriptors of Log P, polar surface 
area, and number of heavy atoms to design/predict other 
anticancer nitrosoureas (with emphasis on targeting pancre-
atic islet cells carcinoma). 
  A more sensitive hierarchical cluster analysis algorithm 
processed numerical values of descriptors to resolve the as-
sociation among streptozocin and analogs. The outcome 
paired streptozocin more closely to analog 3 but with asso-
ciation with analog 6 and 10 at greater Euclidean distance 
within the dendrogram. Other analogs were paired 5 and 8, 2 
and 9, concluding with 4 and 7. This study demonstrated the 
efficacy of modeling analogous compounds to a successful 
parent antineoplastic agent based on molecular isosteres and 
structural analogy. Pattern recognition methods elucidated 
underlying associations within the numerical values of the 
descriptors that are vital in inspecting drug likeness and 
bioavailability. Comparing relative activity scores of strepto-
zocin to those of analogs 2 through 10 utilizing four drug 
classes (GPCR ligand, ion channel modulator, (kinase inhibi-
tor, and nuclear receptor ligand) showed all compounds are 
very highly correlated with expected similar bio-activity. 
Molecular modeling and pattern recognition analysis are 
very useful tools for designing novel chemotherapeutics for 
the treatment of neuroendocrine tumors of the pancreas. 
ABBREVIATIONS 
GEP-NETs  =  Gastro entero pancreatic neuroendocrine  
     tumors 
EPTs =  Endocrine  pancreatic  tumors 
PSA  =  Polar surface area 
ANOSIM =  Analysis  of  Similarity 
DA =  Discriminant  analysis 
ACKNOWLEDGEMENTS 
  This work was supported by the College of Arts & Sci-
ences, Chemistry Department of the University of Nebraska, 
Omaha, NE USA. 
REFERENCES 
[1]  Brentjens, R.; Saltz, L. Islet cell tumors of the pancreas: the medi-
cal oncologist’s perspective. Surg. Clin. North Am., 2001, 81, 527-
42. 
[2]  Wang, A.; Gleichmann, H. GLUT 2 in pancreatic islets: curcial 
target molecule in diabetes. Diabetes, 1998, 47(1), 50-6. 
[3]  Schedl, W.J.; Ferber, S.; Johnson, J.H.; Newgard, C.B. STZ tram-
sport and cytotoxicity. Specific enhancement in GLUT2-expressing 
cells. Diabetes, 1994, 43, 1326-33. 
[4]  Murray-Lyon, I.M.; Eddleston, A.L.; Williams, R.; Brown, M.; 
Hughes, B.W.; Bennet, A.; Edwards, J.C.; Taylor, K.W. Treatment 
of multiple hormone producing malignant islet-cell tumour with 
streptozoticin. Lancet, 1968, 2, 895-8. 
[5]  Horton, J.; Geiber, R.D.; Engstrom, P.; Falkson, G.; Moetel, C.; 
Brodovsky, H.; Douglass, H. Trials of single-agent and combina-
tion chemotherapy for advanced cancer of the pancreas. Cancer 
Treat. Rep., 1981, 65(1-2), 65-8. 
[6]  Arakawa, Y.; Mizunuma, N.; Aiba, K.; Ito, Y.; Takahashi, S.; Ine, 
T.; Watanabe, J.; Tada, K.; Okudaira, J.; Seki, M.; Yamaguchi, T.; 
Muto, T.; Hatake, K. Pancreatic islet cell cancinoma with multiple 
hepatic metastases successfully treated with a streptozocin 5-FU 
regimen-a case report. Cancer Chemother., 2002, 29, 2561-4. 
[7]  Arnold, R.; Rinke, A.; Schmidt, C.; Hofbauer, L. Chemotherapy. 
Best Practice & Research. Clin. Gastroenterol., 2005, 19, 649-56. 
[8]  Kouvaraki, M.A.; Ajani, J.A.; Hoff, P.; Worlff, R.; Evans, D.B.; 
Lozano, R.; Yao, J.C. J. Fluorouracil, doxorubicin, and streptozocin 
in the treatment of patients with locally advanced and metastatic 
pancreatic endocrine carcinomas. J. Clin. Oncol., 2004, 22, 4762-
71. 
[9]  Moertel, C.G.; Lefkopoulo, M.; Lipsitz, S.; Hahn, R.G.; Klaasen, 
D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozo-
tocin in the treatment of acvanced islet-cell carcinoma. N. Engl. J. 
Med., 1992, 326, 519-23. 
[10]  Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar 
surface area as a sum of fragment-based contributions and its appli-
caqtion to the precidtion of drug transport properties. J. Med. 
Chem., 2000, 43, 3714 17. 
[11]  Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Ex-
perimental and computational approaches to estimate solubility and 
permeability in drug discovery and development settings. Adv. 
Drug Deliv. Rev., 2001, 46, 3-26. 
[12]  Livingstone, D.J. Patten recognition methods in rational drug de-
sign. Methods Enzymol., 1991, 203, 613-38. 
[13]  Hudson, B.; Livingsone, D.J.; Rahr, E. Pattern recognition display 
methods for the analysis of computed molecular properties. J. 
Comput. Aided Mol. Des., 1989, 3, 55-65. 
[14]  Duda, R.O.; Hart, P.E.; Stork, D.G. Pattern Classification, Wiley: 
New York, 2001. 
[15]  Bow, S.T. Pattern Recognition, Marcel Dekker: New York, 1984. 
[16]  Clarke, K.R. Non-parametric multivariate analysis of changes in 
community structure. Aust. J. Ecol., 1993, 18, 117-43. 
[17]  Davis, J.C. Statistics and Data Analysis in Geology, John Wiley & 
Sons: New York, 1986. 
 
 
Received: June 23, 2008  Revised: August 12, 2008  Accepted: August 13, 2008 
 
© Ronald Bartzatt; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-
nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. 
 
 